News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News ACC: It’s Time for Clinicians to Address Inflammation in CVD Caitlin E. Cox October 03, 2025
News Conference News ESC 2025 WHF Stresses the Importance of Polypills in Global Fight Against CVD Yael L. Maxwell September 09, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Daily News For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis Yael L. Maxwell August 14, 2025
News Daily News Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050 Todd Neale July 16, 2025
News Daily News FDA Approves Triple Therapy Polypill for High Blood Pressure Michael O'Riordan June 10, 2025
News Daily News Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years Yael L. Maxwell June 09, 2025
News Conference News EuroPCR 2025 ‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI Michael O'Riordan May 29, 2025
News Daily News AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease Caitlin E. Cox May 06, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Use of Secondary CVD Prevention Meds Still Meager Worldwide Caitlin E. Cox February 03, 2025
News Daily News Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD Todd Neale December 06, 2024
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024